A type of electrical therapy called Tumor Treating Fields (TTFields), given in combination with chemotherapy and other medication, may help prevent disease progression in people…
News
GLIX1, a treatment for recurrent and progressive glioblastoma and other high-grade gliomas, has begun human testing in a Phase 1/2a clinical trial, said…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the experimental therapy ZW191 as a potential treatment for hard-to-manage ovarian cancer.
A European Medicines Agency (EMA) panel has recommended approval of a subcutaneous (under-the-skin) version of Sarclisa (isatuximab), an approved myeloma treatment sold by Sanofi. The…
Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion deal aimed at expanding its oncology pipeline, including an experimental treatment for chronic…
Adding Amplia Therapeutics‘ experimental drug narmafotinib to standard chemotherapy led to complete responses — meaning no detectable cancer on imaging scans for at least…
Myosin Therapeutics has been awarded $2 million in funding to support a Phase 1/2 clinical trial testing its lead experimental cancer therapy, MT-125, in…
Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR T-cell therapy for ovarian cancer,…
Tempus AI, a technology company focused on advancing precision medicine using artificial intelligence (AI), has announced a strategic collaboration with the advocacy organization…
Caris Life Sciences has launched a new diagnostic tool that aims to help guide treatment decisions for people with pancreatic ductal adenocarcinoma (PDAC), the…
